SB 1276 Summary

• Moves pseudoephedrine from Schedule V to Schedule III of controlled dangerous substances, making it subject to stricter regulations and prescription requirements

• Exempts liquid, liquid capsule, and gel capsule formulations of pseudoephedrine if it is not the sole active ingredient

• Removes previous over-the-counter sale restrictions for pseudoephedrine, including the 9-gram per 30-day purchase limit and the requirement for written logs and identification checks at pharmacies

• Eliminates reporting requirements for nonprescription sales of pseudoephedrine products, while maintaining reporting requirements only for prescription dispensations of Schedule III controlled substances

• Becomes effective November 1, 2012